Journal
BLOOD
Volume 109, Issue 1, Pages 52-57Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2006-05-021162
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [P01CA108631] Funding Source: NIH RePORTER
- NCI NIH HHS [1P50CA 10063204, P01 CA 108631] Funding Source: Medline
Ask authors/readers for more resources
Epigenetic therapy with hypomethylating drugs is now the standard of care in myelodysplastic syndrome (MDS). Response rates remain low, and mechanism-based dose optimization has not been reported. We investigated the clinical and pharmacodynamic results of different dose schedules of decitabine. Adults with advanced MDS or chronic myelomonocytic leukemia (CMML) were randomized to 1 of 3 decitabine schedules: (1) 20 mg/m(2) intravenously daily for 5 days; (2) 20 mg/m(2) subcutaneously daily for 5 days; and (3) 10 mg/m(2) intravenously daily for 10 days. Randomization followed a Bayesian adaptive design. Ninety-five patients were treated (77 with MDS, and 18 with CMML). Overall, 32 patients (34%) achieved a complete response (CR), and 69 (73%) had an objective response by the new modified International Working Group criteria. The 5-day intravenous schedule, which had the highest dose-intensity, was selected as optimal; the CR rate in that arm was 39%, compared with 21% in the 5-day subcutaneous arm and 24% in the 10-day intravenous arm (P <.05). The high dose-intensity arm was also superior at inducing hypomethylation at day 5 and at activating P15 expression at days 12 or 28 after therapy. We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available